董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Curtis Rosebraugh | 男 | Director | -- | 3.14万美元 | 未持股 | 2023-07-05 |
| Adam S. Levin | 男 | Director | -- | 3.39万美元 | 未持股 | 2023-07-05 |
| Lee Rauch | 女 | Director | -- | 3.69万美元 | 未持股 | 2023-07-05 |
| Steve Martin | 男 | Director | 63 | 3.89万美元 | 未持股 | 2023-07-05 |
| D. Lynn Kirkpatrick | 女 | Chief Executive Officer and Director | 67 | 62.26万美元 | 未持股 | 2023-07-05 |
| Bob Gower | 男 | Chairman | -- | 4.89万美元 | 未持股 | 2023-07-05 |
| William Chang | 男 | Director | -- | 3.14万美元 | 未持股 | 2023-07-05 |
| Andrew Benton | 男 | Director | -- | 3.14万美元 | 未持股 | 2023-07-05 |
| Steve Martin | 男 | Director | -- | 未披露 | 未持股 | 2023-07-05 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David Humphrey | 男 | Chief Financial Officer, Secretary and Treasurer | 55 | 78.06万美元 | 未持股 | 2023-07-05 |
| Jeffrey Millard | 男 | Chief Operating Officer | 48 | 未披露 | 未持股 | 2023-07-05 |
| Linda Pestano | 女 | Chief Development Officer | 55 | 未披露 | 未持股 | 2023-07-05 |
| William Schmidt | 男 | Chief Medical Officer | 72 | 未披露 | 未持股 | 2023-07-05 |
| D. Lynn Kirkpatrick | 女 | Chief Executive Officer and Director | 67 | 62.26万美元 | 未持股 | 2023-07-05 |
| Geoff Birkett | 男 | Chief Commercial Officer | 61 | 36.70万美元 | 未持股 | 2023-07-05 |
董事简历
中英对照 | 中文 | 英文- Curtis Rosebraugh
-
Curtis Rosebraugh，自2021年起担任Ensysce Biosciences, Inc.董事会成员。自2018年5月起，他成为Griebel and Rosebraugh Consulting LLC的成员，担任该公司小分子和生物药物开发的监管顾问。在成立一家咨询公司之前，他自2000年起受雇于美国食品药品监督管理局，从2007年起担任药品审评和研究中心（CDER）的药品审评办公室（ODEII）主任，直到2018年退休，负责监督3个部门内所有药品的评估：肺、过敏和风湿病产品部门、代谢和内分泌产品部门以及麻醉、镇痛和成瘾产品部门。在这一职位上，他监督了50多种新药的开发和批准，负责规划了100多次咨询委员会会议，领导ODE II解决了几个有争议的安全问题，并获得了许多荣誉和奖项。Rosebraugh博士参与了防止滥用的类阿片制剂的开发，还参与了生物仿制药方案以及许多其他CDER倡议的开发。罗斯布劳博士于1981年获得药学本科学位，1986年获得医学学位，1989年获得内科住院医师资格，所有这些都在堪萨斯大学完成。他于1999年在约翰·霍普金斯大学公共卫生学院获得公共卫生硕士学位，并于2000年在乔治敦大学获得临床药理学奖学金。
Curtis Rosebraugh,has served on Ensysce Biosciences, Inc. Board since 2021. He is a member of Griebel and Rosebraugh Consulting LLC since May 2018, where he is a regulatory consultant for small molecule and biological drug development. Prior to forming a consulting firm, he was employed by the Food and Drug Administration since 2000, holding the position of Director of the Office of Drug Evaluation II ("ODEII") within the Center for Drug Evaluation and Research ("CDER") from 2007 until his retirement in 2018, with supervisory responsibility for the evaluation of all drug products within 3 divisions: the Division of Pulmonary, Allergy and Rheumatology Products, the Division of Metabolism and Endocrinology Products and the Division of Anesthesia, Analgesia, and Addiction Products. In this position, he has overseen the development and approval of over 50 new drugs, was responsible for the planning of over 100 advisory committee meetings, led ODE II through several controversial safety issues and has received many honors and awards. Dr. Rosebraugh has been involved in the development of abuse deterrent opioid formulations and has also been involved in the development of the biosimilar program as well as many other CDER initiatives. Dr. Rosebraugh received his undergraduate degree in pharmacy in 1981, his Medical Degree in 1986 and completed a residency in Internal Medicine in 1989, all at the University of Kansas. He completed a Masters of Public Health at Johns Hopkins School of Public Health in 1999 and a Clinical Pharmacology Fellowship at Georgetown University in 2000. - Curtis Rosebraugh，自2021年起担任Ensysce Biosciences, Inc.董事会成员。自2018年5月起，他成为Griebel and Rosebraugh Consulting LLC的成员，担任该公司小分子和生物药物开发的监管顾问。在成立一家咨询公司之前，他自2000年起受雇于美国食品药品监督管理局，从2007年起担任药品审评和研究中心（CDER）的药品审评办公室（ODEII）主任，直到2018年退休，负责监督3个部门内所有药品的评估：肺、过敏和风湿病产品部门、代谢和内分泌产品部门以及麻醉、镇痛和成瘾产品部门。在这一职位上，他监督了50多种新药的开发和批准，负责规划了100多次咨询委员会会议，领导ODE II解决了几个有争议的安全问题，并获得了许多荣誉和奖项。Rosebraugh博士参与了防止滥用的类阿片制剂的开发，还参与了生物仿制药方案以及许多其他CDER倡议的开发。罗斯布劳博士于1981年获得药学本科学位，1986年获得医学学位，1989年获得内科住院医师资格，所有这些都在堪萨斯大学完成。他于1999年在约翰·霍普金斯大学公共卫生学院获得公共卫生硕士学位，并于2000年在乔治敦大学获得临床药理学奖学金。
- Curtis Rosebraugh,has served on Ensysce Biosciences, Inc. Board since 2021. He is a member of Griebel and Rosebraugh Consulting LLC since May 2018, where he is a regulatory consultant for small molecule and biological drug development. Prior to forming a consulting firm, he was employed by the Food and Drug Administration since 2000, holding the position of Director of the Office of Drug Evaluation II ("ODEII") within the Center for Drug Evaluation and Research ("CDER") from 2007 until his retirement in 2018, with supervisory responsibility for the evaluation of all drug products within 3 divisions: the Division of Pulmonary, Allergy and Rheumatology Products, the Division of Metabolism and Endocrinology Products and the Division of Anesthesia, Analgesia, and Addiction Products. In this position, he has overseen the development and approval of over 50 new drugs, was responsible for the planning of over 100 advisory committee meetings, led ODE II through several controversial safety issues and has received many honors and awards. Dr. Rosebraugh has been involved in the development of abuse deterrent opioid formulations and has also been involved in the development of the biosimilar program as well as many other CDER initiatives. Dr. Rosebraugh received his undergraduate degree in pharmacy in 1981, his Medical Degree in 1986 and completed a residency in Internal Medicine in 1989, all at the University of Kansas. He completed a Masters of Public Health at Johns Hopkins School of Public Health in 1999 and a Clinical Pharmacology Fellowship at Georgetown University in 2000.
- Adam S. Levin
-
亚当·S·莱文于2021年6月加入董事会，自2014年起担任约翰斯·霍普金斯大学骨科外科临床操作副主任。他是骨科外科副教授和肿瘤学副教授，研究与肌肉骨骼肿瘤相关的治疗方法，同时保持活跃的临床实践。莱文博士在约翰霍普金斯大学担任Virginia M. Percy和William Algernon Percy的骨科外科讲座。他还在肌肉骨骼肿瘤协会、美国骨科医师学会和美国医学协会担任与计费、编码和实践管理相关的领导职务。在加入约翰·霍普金斯大学之前，莱文博士在2012年至2014年期间担任纽约霍夫斯特拉大学朱克医学院的骨科外科助理教授。2010年至2012年，他在纪念斯隆-凯特琳癌症中心担任肌肉骨骼肿瘤学研究员和临床指导，之后于2005年至2010年在北岸/LIJ卫生系统（现为Northwell Health）接受住院医师培训。他是北岸/LIJ医师高潜力项目、美国骨科医师学会和美国骨科协会领导研究员项目的成员。自2016年以来，莱文博士还继续担任《骨与关节外科杂志》CME的副主编，并且是肌肉骨骼肿瘤登记指导委员会的成员。在Ensysce Biosciences公司的前身LACQ对Ensysce Biosciences公司的临床前和I期临床试验结果进行初步审查期间，Levin博士曾担任该公司的主题顾问。莱文博士拥有康奈尔大学动物生理学的生物学学士学位和纽约医学院的医学博士学位，目前在约翰霍普金斯大学凯里商学院攻读MBA学位，主修医疗保健管理、创新和技术。
Adam S. Levin,joined the Board in June 2021 and is the Vice Chair of Clinical Operations for the Department of Orthopaedic Surgery at Johns Hopkins University, where he has been on faculty since 2014. He is an Associate Professor of Orthopaedic Surgery and Associate Professor of Oncology, researching treatments related to musculoskeletal oncology, while also maintaining an active clinical practice. Dr. Levin holds the Virginia M. Percy and William Algernon Percy Chair in Orthopaedic Surgery at Johns Hopkins University. He serves in additional leadership roles related to billing, coding, and practice management for the Musculoskeletal Tumor Society, the American Academy of Orthopaedic Surgeons, and the American Medical Association. Prior to joining Johns Hopkins University, Dr. Levin was an Assistant Professor of Orthopaedic Surgery at the Zucker School of Medicine at Hofstra University in New York between 2012 and 2014. From 2010 to 2012, he was a fellow of musculoskeletal oncology and Clinical Instructor at Memorial Sloan-Kettering Cancer Center, following his residency training at the North Shore/LIJ Health System (now Northwell Health) from 2005 to 2010. He has been a member of leadership fellows programs through the North Shore/LIJ Physician High Potential Program, the American Academy of Orthopaedic Surgeons, and the American Orthopaedic Association. Dr. Levin has also continued to serve as Associate Editor for CME for the Journal of Bone and Joint Surgery since 2016, and is on the Steering Committee for the Musculoskeletal Tumor Registry. Dr. Levin served as a subject-matter consultant to Ensysce Biosciences, Inc. predecessor, LACQ, during their initial review of Ensysce Biosciences, Inc. preclinical and Phase I clinical trial results. Dr. Levin holds a B.S. in Biology with a concentration in Animal Physiology from Cornell University, an M.D. from New York Medical College, and is currently studying at the Johns Hopkins University Carey School of Business for an M.B.A. with a specialization in Healthcare Management, Innovation, and Technology. - 亚当·S·莱文于2021年6月加入董事会，自2014年起担任约翰斯·霍普金斯大学骨科外科临床操作副主任。他是骨科外科副教授和肿瘤学副教授，研究与肌肉骨骼肿瘤相关的治疗方法，同时保持活跃的临床实践。莱文博士在约翰霍普金斯大学担任Virginia M. Percy和William Algernon Percy的骨科外科讲座。他还在肌肉骨骼肿瘤协会、美国骨科医师学会和美国医学协会担任与计费、编码和实践管理相关的领导职务。在加入约翰·霍普金斯大学之前，莱文博士在2012年至2014年期间担任纽约霍夫斯特拉大学朱克医学院的骨科外科助理教授。2010年至2012年，他在纪念斯隆-凯特琳癌症中心担任肌肉骨骼肿瘤学研究员和临床指导，之后于2005年至2010年在北岸/LIJ卫生系统（现为Northwell Health）接受住院医师培训。他是北岸/LIJ医师高潜力项目、美国骨科医师学会和美国骨科协会领导研究员项目的成员。自2016年以来，莱文博士还继续担任《骨与关节外科杂志》CME的副主编，并且是肌肉骨骼肿瘤登记指导委员会的成员。在Ensysce Biosciences公司的前身LACQ对Ensysce Biosciences公司的临床前和I期临床试验结果进行初步审查期间，Levin博士曾担任该公司的主题顾问。莱文博士拥有康奈尔大学动物生理学的生物学学士学位和纽约医学院的医学博士学位，目前在约翰霍普金斯大学凯里商学院攻读MBA学位，主修医疗保健管理、创新和技术。
- Adam S. Levin,joined the Board in June 2021 and is the Vice Chair of Clinical Operations for the Department of Orthopaedic Surgery at Johns Hopkins University, where he has been on faculty since 2014. He is an Associate Professor of Orthopaedic Surgery and Associate Professor of Oncology, researching treatments related to musculoskeletal oncology, while also maintaining an active clinical practice. Dr. Levin holds the Virginia M. Percy and William Algernon Percy Chair in Orthopaedic Surgery at Johns Hopkins University. He serves in additional leadership roles related to billing, coding, and practice management for the Musculoskeletal Tumor Society, the American Academy of Orthopaedic Surgeons, and the American Medical Association. Prior to joining Johns Hopkins University, Dr. Levin was an Assistant Professor of Orthopaedic Surgery at the Zucker School of Medicine at Hofstra University in New York between 2012 and 2014. From 2010 to 2012, he was a fellow of musculoskeletal oncology and Clinical Instructor at Memorial Sloan-Kettering Cancer Center, following his residency training at the North Shore/LIJ Health System (now Northwell Health) from 2005 to 2010. He has been a member of leadership fellows programs through the North Shore/LIJ Physician High Potential Program, the American Academy of Orthopaedic Surgeons, and the American Orthopaedic Association. Dr. Levin has also continued to serve as Associate Editor for CME for the Journal of Bone and Joint Surgery since 2016, and is on the Steering Committee for the Musculoskeletal Tumor Registry. Dr. Levin served as a subject-matter consultant to Ensysce Biosciences, Inc. predecessor, LACQ, during their initial review of Ensysce Biosciences, Inc. preclinical and Phase I clinical trial results. Dr. Levin holds a B.S. in Biology with a concentration in Animal Physiology from Cornell University, an M.D. from New York Medical College, and is currently studying at the Johns Hopkins University Carey School of Business for an M.B.A. with a specialization in Healthcare Management, Innovation, and Technology.
- Lee Rauch
-
Lee Rauch，自2022年2月起担任Ensysce Biosciences, Inc.董事会成员。她是一位经验丰富的首席执行官和战略顾问，曾为上市公司和私营公司服务。在她近40年的职业生涯中，劳赫女士成功地建立了从临床前研究到高级临床开发的各种公司，牵头进行并购，Ensysce Biosciences公司利用她的经验为公共和私营生物技术公司争取到融资。在她的许多领导角色中，劳赫女士是麦肯锡国际制药实践的创始成员和Springboard Enterprises Health Innovation Hub的执行主席。最近，Rauch女士担任Viridian Therapeutics, Inc.的总裁兼首席执行官。Rauch女士在亚利桑那州立大学获得化学学士学位，在芝加哥大学获得金融工商管理硕士学位。
Lee Rauch,has served on Ensysce Biosciences, Inc. Board since February 2022. She is an experienced Chief Executive Officer and Strategy Advisor, has served both public and private companies. During her near 40-year career, Ms. Rauch successful built companies ranging in focus from pre-clinical research to advanced clinical development, took the lead in mergers and acquisitions and Ensysce Biosciences, Inc. ed her experience to secure financing for public and private biotech companies. Among her many leadership roles, Ms. Rauch, was notably a founding member of McKinsey & Co.'s International Pharmaceutical Practice and the Executive Chairman of Springboard Enterprises Health Innovation Hub. Most recently, Ms. Rauch, served as President and CEO of Viridian Therapeutics, Inc. Ms. Rauch received a B.S. in Chemistry from Arizona State University and an M.B.A. in Finance from the University of Chicago. - Lee Rauch，自2022年2月起担任Ensysce Biosciences, Inc.董事会成员。她是一位经验丰富的首席执行官和战略顾问，曾为上市公司和私营公司服务。在她近40年的职业生涯中，劳赫女士成功地建立了从临床前研究到高级临床开发的各种公司，牵头进行并购，Ensysce Biosciences公司利用她的经验为公共和私营生物技术公司争取到融资。在她的许多领导角色中，劳赫女士是麦肯锡国际制药实践的创始成员和Springboard Enterprises Health Innovation Hub的执行主席。最近，Rauch女士担任Viridian Therapeutics, Inc.的总裁兼首席执行官。Rauch女士在亚利桑那州立大学获得化学学士学位，在芝加哥大学获得金融工商管理硕士学位。
- Lee Rauch,has served on Ensysce Biosciences, Inc. Board since February 2022. She is an experienced Chief Executive Officer and Strategy Advisor, has served both public and private companies. During her near 40-year career, Ms. Rauch successful built companies ranging in focus from pre-clinical research to advanced clinical development, took the lead in mergers and acquisitions and Ensysce Biosciences, Inc. ed her experience to secure financing for public and private biotech companies. Among her many leadership roles, Ms. Rauch, was notably a founding member of McKinsey & Co.'s International Pharmaceutical Practice and the Executive Chairman of Springboard Enterprises Health Innovation Hub. Most recently, Ms. Rauch, served as President and CEO of Viridian Therapeutics, Inc. Ms. Rauch received a B.S. in Chemistry from Arizona State University and an M.B.A. in Finance from the University of Chicago.
- Steve Martin
-
Steve Martin，自2011年6月起担任本公司高级副总裁兼财务总监；2012年11月至2013年3月，担任本公司临时首席执行官；2013年9月，他被任命为公司秘书。他是一名注册会计师，拥有超过25年的财务工作领导经历，并在包括生命科学在内的多个行业的上市公司体现了深厚的专业知识。2008-2011，他担任软件上市公司BakBone Software的高级副总裁兼首席财务官；他还在该公司担任了10个月的临时首席执行官，使得该公司2011年1月销售增加。2007-2008，他担任年收入达20亿美元的电信公司Leap Wireless International的顾问和首席财务官。2005-2007，他担任上市公司Stratagene Corporation的首席财务官，该公司专门从事专业研究与临床诊断产品的开发、制造和营销。之前，他还曾担任上市公司Gen-Probe Incorporated 的财务总监，该公司后来被生命科学公司Hologic收购；另外，他还在德勤会计师事务所工作了10年。他获得了圣地亚哥州立大学的理科学士学位。
Steve Martin has served as Senior Vice President and Chief Financial Officer of Seelos Therapeutics, Inc. since June 2011 and served as Interim Chief Executive Officer for the period of Seelos Therapeutics, Inc. from November 2012 through March 2013. Mr. Martin was appointed the Company's Secretary in September 2013. Mr. Martin is a certified public accountant, with over twenty-five years of financial leadership, with significant expertise in growing public companies in a variety of industries, including the life sciences. From 2008 to 2011 Mr. Martin served as Senior Vice President and Chief Financial Officer of BakBone Software, a publicly-traded software company. Mr. Martin also served as Interim CEO for ten months with BakBone, leading up to the sale of the Company in January of 2011. During 2007 and 2008 Mr. Martin served as a Consultant and as the Chief Accounting Officer of Leap Wireless International, a $2 billion revenue telecommunications company. From 2005 to 2007 Mr. Martin served as Chief Financial Officer of Stratagene Corporation, a publicly traded company specializing in the development, manufacture and marketing of specialized research and clinical diagnostic products. Mr. Martin's previous experience also includes the position of Controller with publicly traded Gen-Probe Incorporated acquired by Hologic, Inc., a life sciences company, as well as ten years with the public accounting firm of Deloitte & Touche. Mr. Martin holds a Bachelors of Science degree from San Diego State University. - Steve Martin，自2011年6月起担任本公司高级副总裁兼财务总监；2012年11月至2013年3月，担任本公司临时首席执行官；2013年9月，他被任命为公司秘书。他是一名注册会计师，拥有超过25年的财务工作领导经历，并在包括生命科学在内的多个行业的上市公司体现了深厚的专业知识。2008-2011，他担任软件上市公司BakBone Software的高级副总裁兼首席财务官；他还在该公司担任了10个月的临时首席执行官，使得该公司2011年1月销售增加。2007-2008，他担任年收入达20亿美元的电信公司Leap Wireless International的顾问和首席财务官。2005-2007，他担任上市公司Stratagene Corporation的首席财务官，该公司专门从事专业研究与临床诊断产品的开发、制造和营销。之前，他还曾担任上市公司Gen-Probe Incorporated 的财务总监，该公司后来被生命科学公司Hologic收购；另外，他还在德勤会计师事务所工作了10年。他获得了圣地亚哥州立大学的理科学士学位。
- Steve Martin has served as Senior Vice President and Chief Financial Officer of Seelos Therapeutics, Inc. since June 2011 and served as Interim Chief Executive Officer for the period of Seelos Therapeutics, Inc. from November 2012 through March 2013. Mr. Martin was appointed the Company's Secretary in September 2013. Mr. Martin is a certified public accountant, with over twenty-five years of financial leadership, with significant expertise in growing public companies in a variety of industries, including the life sciences. From 2008 to 2011 Mr. Martin served as Senior Vice President and Chief Financial Officer of BakBone Software, a publicly-traded software company. Mr. Martin also served as Interim CEO for ten months with BakBone, leading up to the sale of the Company in January of 2011. During 2007 and 2008 Mr. Martin served as a Consultant and as the Chief Accounting Officer of Leap Wireless International, a $2 billion revenue telecommunications company. From 2005 to 2007 Mr. Martin served as Chief Financial Officer of Stratagene Corporation, a publicly traded company specializing in the development, manufacture and marketing of specialized research and clinical diagnostic products. Mr. Martin's previous experience also includes the position of Controller with publicly traded Gen-Probe Incorporated acquired by Hologic, Inc., a life sciences company, as well as ten years with the public accounting firm of Deloitte & Touche. Mr. Martin holds a Bachelors of Science degree from San Diego State University.
- D. Lynn Kirkpatrick
-
D. Lynn Kirkpatrick，自2009年1月起担任Ensysce Biosciences, Inc.首席执行官。柯克帕特里克博士在药物发现和开发方面花费了30多年时间，启动了四种新型候选药物的临床开发，目前正致力于将高度新颖和安全的疼痛疗法推向商业化。她在萨斯喀彻温大学获得医药和生物医药化学哲学博士（“Ph.D.”）学位，在耶鲁大学医学院完成博士后奖学金，并成为里贾纳大学化学系终身正教授。她与人共同创立了一家肿瘤发现公司ProlX Pharmaceuticals，Corp.（简称ProlX），成为首席执行官，并成功地将三个小分子的发现带入临床开发，其中两个是她自己在学术界的发现。ProlX被Biomira公司收购，柯克帕特里克博士成为合并后公司的首席科学官，专注于肿瘤产品和疫苗的开发。2009年，她与人共同创立了PHusis Therapeutics，开发针对肿瘤的小分子精准药物。同时，她成为了Ensysce Biosciences, Inc.的首席执行官。Kirkpatrick博士在靶向药物发现领域发表了大量文章，滥用具有威慑力的止痛产品，并拥有许多新药和新药的专利。
D. Lynn Kirkpatrick,has served as Ensysce Biosciences, Inc. Chief Executive Officer since January 2009. She received a Doctor of Philosophy ("Ph.D.") degree in Medicinal and Biomedicinal Chemistry at the University of Saskatchewan, completed a Post-Doctoral Fellowship at the Yale University School of Medicine, and became a tenured full professor in the Department of Chemistry at the University of Regina. She co-founded ProlX Pharmaceuticals, Corp. ("ProlX") an oncology discovery company, becoming Chief Executive Officer. ProlX was acquired by Biomira Inc., and Dr. Kirkpatrick became the Chief Scientific Officer of the merged company to focus on the development of oncology products and vaccines. In 2009, she co-founded PHusis Therapeutics, developing targeted small molecule precision medicines for oncology. At the same time, she became Ensysce Biosciences, Inc. Chief Executive Officer. - D. Lynn Kirkpatrick，自2009年1月起担任Ensysce Biosciences, Inc.首席执行官。柯克帕特里克博士在药物发现和开发方面花费了30多年时间，启动了四种新型候选药物的临床开发，目前正致力于将高度新颖和安全的疼痛疗法推向商业化。她在萨斯喀彻温大学获得医药和生物医药化学哲学博士（“Ph.D.”）学位，在耶鲁大学医学院完成博士后奖学金，并成为里贾纳大学化学系终身正教授。她与人共同创立了一家肿瘤发现公司ProlX Pharmaceuticals，Corp.（简称ProlX），成为首席执行官，并成功地将三个小分子的发现带入临床开发，其中两个是她自己在学术界的发现。ProlX被Biomira公司收购，柯克帕特里克博士成为合并后公司的首席科学官，专注于肿瘤产品和疫苗的开发。2009年，她与人共同创立了PHusis Therapeutics，开发针对肿瘤的小分子精准药物。同时，她成为了Ensysce Biosciences, Inc.的首席执行官。Kirkpatrick博士在靶向药物发现领域发表了大量文章，滥用具有威慑力的止痛产品，并拥有许多新药和新药的专利。
- D. Lynn Kirkpatrick,has served as Ensysce Biosciences, Inc. Chief Executive Officer since January 2009. She received a Doctor of Philosophy ("Ph.D.") degree in Medicinal and Biomedicinal Chemistry at the University of Saskatchewan, completed a Post-Doctoral Fellowship at the Yale University School of Medicine, and became a tenured full professor in the Department of Chemistry at the University of Regina. She co-founded ProlX Pharmaceuticals, Corp. ("ProlX") an oncology discovery company, becoming Chief Executive Officer. ProlX was acquired by Biomira Inc., and Dr. Kirkpatrick became the Chief Scientific Officer of the merged company to focus on the development of oncology products and vaccines. In 2009, she co-founded PHusis Therapeutics, developing targeted small molecule precision medicines for oncology. At the same time, she became Ensysce Biosciences, Inc. Chief Executive Officer.
- Bob Gower
-
鲍勃·高尔，自2008年起担任Ensysce Biosciences, Inc.董事长。高尔博士从1985年开始担任利安德尔石油化工公司的首席执行官，直到1996年底退休。1997年，他从豪厄尔公司收购了一些业务，成为特定燃料和化学品公司。高尔博士于2000年出售了Specified，并与理查德·斯莫利博士于同年成立了Carbon Nanotechnologies，Inc.（CNI），以开发单壁碳纳米管的生产能力和应用。CNI于2007年被Unidym收购。高尔博士于2008年创立了Ensysce，专注于Ensysce Biosciences公司，致力于治疗领域的单壁碳纳米管。Ensysce随后与Signature Therapeutics，Inc.合并，并将重点转向开发安全的类阿片止痛药。他曾担任多家上市公司的董事会成员，包括Kirby Corporation、OmNova和Keystone。他还参与过并将继续参与几个非盈利组织的工作，特别关注休斯顿学校社区，这是一个领先的辍学预防和心理健康项目，以及南伊利诺伊大学的化学系。高尔博士在SIU获得学士学位，在明尼苏达大学获得博士学位。
Bob Gower,has served as Ensysce Biosciences, Inc. Chairman since 2008. Dr. Gower was Chief Executive Officer of Lyondell Petrochemical from 1985 through his retirement at the end of 1996. In 1997, he acquired businesses from Howell Corporation that became Specified Fuels and Chemicals. Dr. Gower sold Specified in 2000 and, with Dr. Richard Smalley, founded Carbon Nanotechnologies, Inc. ("CNI") that same year to develop production capabilities and applications for single wall carbon nanotubes. CNI was acquired by Unidym in 2007. Dr. Gower founded Ensysce in 2008 with the focus of Ensysce Biosciences, Inc. ing single wall carbon nanotubes in therapeutic areas. Ensysce subsequently merged with Signature Therapeutics, Inc. and changed its focus to developing safe opioid pain drugs. He has served on the Board of Directors of several public companies, including Kirby Corporation, OmNova and Keystone. He also has been and continues to be involved with several not for profit organizations and has especially focused on Communities In Schools Houston, a leading dropout prevention and mental health program, and on Southern Illinois University with focus on the chemistry department. Dr. Gower received his B.S. from SIU and his Ph.D. from the University of Minnesota. - 鲍勃·高尔，自2008年起担任Ensysce Biosciences, Inc.董事长。高尔博士从1985年开始担任利安德尔石油化工公司的首席执行官，直到1996年底退休。1997年，他从豪厄尔公司收购了一些业务，成为特定燃料和化学品公司。高尔博士于2000年出售了Specified，并与理查德·斯莫利博士于同年成立了Carbon Nanotechnologies，Inc.（CNI），以开发单壁碳纳米管的生产能力和应用。CNI于2007年被Unidym收购。高尔博士于2008年创立了Ensysce，专注于Ensysce Biosciences公司，致力于治疗领域的单壁碳纳米管。Ensysce随后与Signature Therapeutics，Inc.合并，并将重点转向开发安全的类阿片止痛药。他曾担任多家上市公司的董事会成员，包括Kirby Corporation、OmNova和Keystone。他还参与过并将继续参与几个非盈利组织的工作，特别关注休斯顿学校社区，这是一个领先的辍学预防和心理健康项目，以及南伊利诺伊大学的化学系。高尔博士在SIU获得学士学位，在明尼苏达大学获得博士学位。
- Bob Gower,has served as Ensysce Biosciences, Inc. Chairman since 2008. Dr. Gower was Chief Executive Officer of Lyondell Petrochemical from 1985 through his retirement at the end of 1996. In 1997, he acquired businesses from Howell Corporation that became Specified Fuels and Chemicals. Dr. Gower sold Specified in 2000 and, with Dr. Richard Smalley, founded Carbon Nanotechnologies, Inc. ("CNI") that same year to develop production capabilities and applications for single wall carbon nanotubes. CNI was acquired by Unidym in 2007. Dr. Gower founded Ensysce in 2008 with the focus of Ensysce Biosciences, Inc. ing single wall carbon nanotubes in therapeutic areas. Ensysce subsequently merged with Signature Therapeutics, Inc. and changed its focus to developing safe opioid pain drugs. He has served on the Board of Directors of several public companies, including Kirby Corporation, OmNova and Keystone. He also has been and continues to be involved with several not for profit organizations and has especially focused on Communities In Schools Houston, a leading dropout prevention and mental health program, and on Southern Illinois University with focus on the chemistry department. Dr. Gower received his B.S. from SIU and his Ph.D. from the University of Minnesota.
- William Chang
-
William Chang，现任Westlake Realty Group首席执行官兼Westlake International Group主席，他在Westlake International Group工作了40多年。张先生是美国职棒大联盟旧金山巨人队的投资者。张成泽曾任美国橄榄球联盟主席。他还担任亚洲基金会和旧金山港口和社会服务委员会的董事会成员。张先生拥有哈佛大学经济学学士学位。
William Chang,serves as Chief Executive Officer of Westlake Realty Group and Chairman of Westlake International Group where he has worked for more than 40 years. Mr. Chang is an investor in the San Francisco Giants of Major League Baseball. Mr. Chang was the former Chairman of U.S. Rugby Football Union. He also served on the Board of the Asia Foundation and San Francisco Port and Social Services Commissions. Mr. Chang holds a Bachelor's degree in Economics from Harvard University. - William Chang，现任Westlake Realty Group首席执行官兼Westlake International Group主席，他在Westlake International Group工作了40多年。张先生是美国职棒大联盟旧金山巨人队的投资者。张成泽曾任美国橄榄球联盟主席。他还担任亚洲基金会和旧金山港口和社会服务委员会的董事会成员。张先生拥有哈佛大学经济学学士学位。
- William Chang,serves as Chief Executive Officer of Westlake Realty Group and Chairman of Westlake International Group where he has worked for more than 40 years. Mr. Chang is an investor in the San Francisco Giants of Major League Baseball. Mr. Chang was the former Chairman of U.S. Rugby Football Union. He also served on the Board of the Asia Foundation and San Francisco Port and Social Services Commissions. Mr. Chang holds a Bachelor's degree in Economics from Harvard University.
- Andrew Benton
-
Andrew Benton，自2019年12月2日起担任Ensysce Biosciences, Inc.董事会成员。2000年6月至2019年7月，本顿先生担任佩珀代因大学校长、首席执行官和受托人。本顿曾任美国教育委员会主席，该委员会是美国所有高等教育机构的主要协调机构，也曾任美国独立学院和大学协会主席。本顿也是加州独立学院和大学协会的前任主席，以及美国律师协会、高等教育认证委员会、西海岸会议总统内阁、独立学院和大学校长协会和洛杉矶世界事务理事会的成员。本顿拥有俄克拉荷马基督教大学的美国研究本科学位和俄克拉荷马大学的法学博士学位。
Andrew Benton,has served as a member of Ensysce Biosciences, Inc. Board since December 2, 2019. Mr. Benton was the President, Chief Executive Officer and Trustee of Pepperdine University from June 2000 to July 2019. Mr. Benton was the former chairman of both the American Council of Education, the major coordinating body for all of the nation's higher education institutions, and the National Association of Independent Colleges and Universities. Mr. Benton is also past chair of the Association of Independent California Colleges and Universities and a member of the American Bar Association, the Council for Higher Education Accreditation, the President's Cabinet of the West Coast Conference, the Association of Presidents of Independent Colleges and Universities, and the Los Angeles World Affairs Council. Mr. Benton holds an undergraduate degree in American studies from Oklahoma Christian University and a J.D. from Oklahoma University. - Andrew Benton，自2019年12月2日起担任Ensysce Biosciences, Inc.董事会成员。2000年6月至2019年7月，本顿先生担任佩珀代因大学校长、首席执行官和受托人。本顿曾任美国教育委员会主席，该委员会是美国所有高等教育机构的主要协调机构，也曾任美国独立学院和大学协会主席。本顿也是加州独立学院和大学协会的前任主席，以及美国律师协会、高等教育认证委员会、西海岸会议总统内阁、独立学院和大学校长协会和洛杉矶世界事务理事会的成员。本顿拥有俄克拉荷马基督教大学的美国研究本科学位和俄克拉荷马大学的法学博士学位。
- Andrew Benton,has served as a member of Ensysce Biosciences, Inc. Board since December 2, 2019. Mr. Benton was the President, Chief Executive Officer and Trustee of Pepperdine University from June 2000 to July 2019. Mr. Benton was the former chairman of both the American Council of Education, the major coordinating body for all of the nation's higher education institutions, and the National Association of Independent Colleges and Universities. Mr. Benton is also past chair of the Association of Independent California Colleges and Universities and a member of the American Bar Association, the Council for Higher Education Accreditation, the President's Cabinet of the West Coast Conference, the Association of Presidents of Independent Colleges and Universities, and the Los Angeles World Affairs Council. Mr. Benton holds an undergraduate degree in American studies from Oklahoma Christian University and a J.D. from Oklahoma University.
- Steve Martin
-
Steve Martin，自2020年8月起担任Ensysce Biosciences, Inc.董事会成员。马丁先生曾任Armata Pharmaceuticals, Inc.高级副总裁兼首席财务官，该公司是一家在纽约证券交易所上市的处于临床开发阶段的生物技术公司，自2016年1月起至2022年6月30日退休。此前，马丁先生曾于2014年12月至2015年8月担任分子诊断公司Applied Proteomics，Inc.的高级副总裁兼首席财务官。2011年6月至2014年12月，Martin先生担任上市制药公司Apricus Biosciences，Inc.（“Apricus”）的高级副总裁兼首席财务官，并于2012年11月至2013年3月担任Apricus的临时首席执行官。2008年至2011年1月，Martin先生担任上市软件公司BakBone Software（“BakBone”）的高级副总裁兼首席财务官。在2011年1月收购BakBone之前的最后10个月里，马丁还担任过BakBone的临时首席执行官。2005年至2007年，马丁先生担任Stratagene公司的首席财务官，该公司是一家上市的研究产品和临床诊断公司。马丁先生之前的经历还包括在一家公开上市的分子诊断公司真探测担任财务总监，以及在一家公共会计师事务所德勤会计师事务所工作了10年。Martin先生拥有圣地亚哥州立大学会计学学士学位，是一名注册会计师（非在职）。
Steve Martin,has served as a member of Ensysce Biosciences, Inc. Board since August 2020. Mr. Martin was formerly Senior Vice President and Chief Financial Officer of Armata Pharmaceuticals, Inc., a clinical development stage biotechnology company listed on New York Stock Exchange, from January 2016 until his retirement from the position on June 30, 2022. Previously, Mr. Martin served as Senior Vice President and Chief Financial Officer of Applied Proteomics, Inc., a molecular diagnostics company, from December 2014 to August 2015. From June 2011 to December 2014, Mr. Martin served as Senior Vice President and Chief Financial Officer of Apricus Biosciences, Inc. ("Apricus"), a publicly traded pharmaceutical company, and served as the Interim Chief Executive Officer of Apricus from November 2012 through March 2013. From 2008 to January 2011, Mr. Martin served as Senior Vice President and Chief Financial Officer of BakBone Software ("BakBone"), a publicly traded software company. During his final 10 months with BakBone until the company's acquisition in January 2011, Mr. Martin also served as BakBone's Interim Chief Executive Officer. From 2005 to 2007, Mr. Martin served as Chief Financial Officer of Stratagene Corporation, a publicly traded research products and clinical diagnostics company. Mr. Martin's previous experience also includes serving as Controller with Gen-Probe Incorporated, a publicly traded molecular diagnostics company, as well as 10 years with Deloitte & Touche LLP, a public accounting firm. Mr. Martin holds a Bachelor in Science in Accounting from San Diego State University and is a certified public accountant (inactive). - Steve Martin，自2020年8月起担任Ensysce Biosciences, Inc.董事会成员。马丁先生曾任Armata Pharmaceuticals, Inc.高级副总裁兼首席财务官，该公司是一家在纽约证券交易所上市的处于临床开发阶段的生物技术公司，自2016年1月起至2022年6月30日退休。此前，马丁先生曾于2014年12月至2015年8月担任分子诊断公司Applied Proteomics，Inc.的高级副总裁兼首席财务官。2011年6月至2014年12月，Martin先生担任上市制药公司Apricus Biosciences，Inc.（“Apricus”）的高级副总裁兼首席财务官，并于2012年11月至2013年3月担任Apricus的临时首席执行官。2008年至2011年1月，Martin先生担任上市软件公司BakBone Software（“BakBone”）的高级副总裁兼首席财务官。在2011年1月收购BakBone之前的最后10个月里，马丁还担任过BakBone的临时首席执行官。2005年至2007年，马丁先生担任Stratagene公司的首席财务官，该公司是一家上市的研究产品和临床诊断公司。马丁先生之前的经历还包括在一家公开上市的分子诊断公司真探测担任财务总监，以及在一家公共会计师事务所德勤会计师事务所工作了10年。Martin先生拥有圣地亚哥州立大学会计学学士学位，是一名注册会计师（非在职）。
- Steve Martin,has served as a member of Ensysce Biosciences, Inc. Board since August 2020. Mr. Martin was formerly Senior Vice President and Chief Financial Officer of Armata Pharmaceuticals, Inc., a clinical development stage biotechnology company listed on New York Stock Exchange, from January 2016 until his retirement from the position on June 30, 2022. Previously, Mr. Martin served as Senior Vice President and Chief Financial Officer of Applied Proteomics, Inc., a molecular diagnostics company, from December 2014 to August 2015. From June 2011 to December 2014, Mr. Martin served as Senior Vice President and Chief Financial Officer of Apricus Biosciences, Inc. ("Apricus"), a publicly traded pharmaceutical company, and served as the Interim Chief Executive Officer of Apricus from November 2012 through March 2013. From 2008 to January 2011, Mr. Martin served as Senior Vice President and Chief Financial Officer of BakBone Software ("BakBone"), a publicly traded software company. During his final 10 months with BakBone until the company's acquisition in January 2011, Mr. Martin also served as BakBone's Interim Chief Executive Officer. From 2005 to 2007, Mr. Martin served as Chief Financial Officer of Stratagene Corporation, a publicly traded research products and clinical diagnostics company. Mr. Martin's previous experience also includes serving as Controller with Gen-Probe Incorporated, a publicly traded molecular diagnostics company, as well as 10 years with Deloitte & Touche LLP, a public accounting firm. Mr. Martin holds a Bachelor in Science in Accounting from San Diego State University and is a certified public accountant (inactive).
高管简历
中英对照 | 中文 | 英文- David Humphrey
David Humphrey，自2021年2月起担任Ensysce Biosciences, Inc.。在加入公司之前，汉弗莱先生最近担任Senomyx, Inc.（“Senomyx”）的首席财务官，该公司是一家专注于味觉科学的上市生物技术公司。在之前的工作中，他指导上市公司财务报告，包括10-K、10-Q、8-K、S-3、S-8表格、代理声明和SOX内部控制合规，并担任审计委员会和外部审计师的主要联络人。作为核心执行管理团队的一员，韩飞龙为Senomyx的董事会提供了咨询服务。瑞士私营跨国香精香料公司芬美意集团以7500万美元收购了该公司。此前，他曾担任财务和会计领导职位，并在多家生命科学公司担任顾问，包括ActivX Biosciences、Aurora Biosciences和Gensia。韩飞龙的职业生涯始于普华永道会计师事务所。他拥有伊利诺伊大学厄巴纳-香槟分校会计学荣誉学士学位，并且是加利福尼亚州的注册会计师。
David Humphrey,has served as Ensysce Biosciences, Inc. Chief Financial Officer since February 2021. Prior to joining the Company, Mr. Humphrey was most recently Chief Financial Officer of Senomyx, Inc. ("Senomyx"), a publicly held biotechnology company focused on taste science. In his previous employment, he guided public company financial reporting, including Forms 10-K, 10-Q, 8-K, S-3, S-8, proxy statements and SOX internal controls compliance, and acted as primary liaison with the audit committee and external auditors. Mr. Humphrey advised Senomyx's board of directors, as part of core executive management team, in a $75 million acquisition by Firmenich SA, a private Swiss multinational flavor and fragrance company. Previously, he held finance and accounting leadership positions and consulted at numerous life sciences companies, including ActivX Biosciences, Aurora Biosciences and Gensia. Mr. Humphrey started his career as an accountant at Price Waterhouse. He holds a Bachelor of Science with Honors in Accountancy from the University of Illinois at Urbana-Champaign and is a Certified Public Accountant in California.- David Humphrey，自2021年2月起担任Ensysce Biosciences, Inc.。在加入公司之前，汉弗莱先生最近担任Senomyx, Inc.（“Senomyx”）的首席财务官，该公司是一家专注于味觉科学的上市生物技术公司。在之前的工作中，他指导上市公司财务报告，包括10-K、10-Q、8-K、S-3、S-8表格、代理声明和SOX内部控制合规，并担任审计委员会和外部审计师的主要联络人。作为核心执行管理团队的一员，韩飞龙为Senomyx的董事会提供了咨询服务。瑞士私营跨国香精香料公司芬美意集团以7500万美元收购了该公司。此前，他曾担任财务和会计领导职位，并在多家生命科学公司担任顾问，包括ActivX Biosciences、Aurora Biosciences和Gensia。韩飞龙的职业生涯始于普华永道会计师事务所。他拥有伊利诺伊大学厄巴纳-香槟分校会计学荣誉学士学位，并且是加利福尼亚州的注册会计师。
- David Humphrey,has served as Ensysce Biosciences, Inc. Chief Financial Officer since February 2021. Prior to joining the Company, Mr. Humphrey was most recently Chief Financial Officer of Senomyx, Inc. ("Senomyx"), a publicly held biotechnology company focused on taste science. In his previous employment, he guided public company financial reporting, including Forms 10-K, 10-Q, 8-K, S-3, S-8, proxy statements and SOX internal controls compliance, and acted as primary liaison with the audit committee and external auditors. Mr. Humphrey advised Senomyx's board of directors, as part of core executive management team, in a $75 million acquisition by Firmenich SA, a private Swiss multinational flavor and fragrance company. Previously, he held finance and accounting leadership positions and consulted at numerous life sciences companies, including ActivX Biosciences, Aurora Biosciences and Gensia. Mr. Humphrey started his career as an accountant at Price Waterhouse. He holds a Bachelor of Science with Honors in Accountancy from the University of Illinois at Urbana-Champaign and is a Certified Public Accountant in California.
- Jeffrey Millard
Jeffrey Millard，自2019年1月起担任Ensysce Biosciences, Inc.首席运营官。Millard博士在化学和制药科学领域拥有学术和工业经验，涵盖化学、制造和控制的各个方面。他既参与过初创生物技术公司，也参与过中小型上市生物制药公司。Millard博士直接负责研究和开发活动，并撰写了七份以上的IND报告和调查医药产品档案。他指导了CMC的工作，从发现和进入许可到商业发射活动。他的经验包括应用程序编程接口，或API，生命周期（从合成路线搜索，过程化学，分析化学开发和验证，API的cGMP生产和发布，到QbD和过程验证），以及从制造到药品开发。米勒德博士在莱斯大学获得文学学士学位，在亚利桑那大学获得药物科学博士学位。
Jeffrey Millard,has served as Ensysce Biosciences, Inc. Chief Operating Officer since January 2019. Dr. Millard has both academic and industrial experience in chemistry and pharmaceutical sciences covering all aspects of chemistry, manufacturing, and controls, or CMC. He has been involved in both start-up biotech as well as small and mid-sized public biopharmaceutical companies. Dr. Millard has been directly responsible for research and development activities and writing of more than seven IND submissions and Investigational Medicinal Product Dossiers, or IMPDs. He has directed the CMC efforts from discovery and in-licensing through commercial launch activities. His experience covers the application programming interface, or API, lifecycle (from synthetic route scouting, process chemistry, analytical chemistry development and validation, cGMP production and release of API, to QbD and process validation), and drug product development through manufacture. Dr. Millard received a Bachelor of Arts from Rice University and a Ph.D. in Pharmaceutical Sciences from the University of Arizona.- Jeffrey Millard，自2019年1月起担任Ensysce Biosciences, Inc.首席运营官。Millard博士在化学和制药科学领域拥有学术和工业经验，涵盖化学、制造和控制的各个方面。他既参与过初创生物技术公司，也参与过中小型上市生物制药公司。Millard博士直接负责研究和开发活动，并撰写了七份以上的IND报告和调查医药产品档案。他指导了CMC的工作，从发现和进入许可到商业发射活动。他的经验包括应用程序编程接口，或API，生命周期（从合成路线搜索，过程化学，分析化学开发和验证，API的cGMP生产和发布，到QbD和过程验证），以及从制造到药品开发。米勒德博士在莱斯大学获得文学学士学位，在亚利桑那大学获得药物科学博士学位。
- Jeffrey Millard,has served as Ensysce Biosciences, Inc. Chief Operating Officer since January 2019. Dr. Millard has both academic and industrial experience in chemistry and pharmaceutical sciences covering all aspects of chemistry, manufacturing, and controls, or CMC. He has been involved in both start-up biotech as well as small and mid-sized public biopharmaceutical companies. Dr. Millard has been directly responsible for research and development activities and writing of more than seven IND submissions and Investigational Medicinal Product Dossiers, or IMPDs. He has directed the CMC efforts from discovery and in-licensing through commercial launch activities. His experience covers the application programming interface, or API, lifecycle (from synthetic route scouting, process chemistry, analytical chemistry development and validation, cGMP production and release of API, to QbD and process validation), and drug product development through manufacture. Dr. Millard received a Bachelor of Arts from Rice University and a Ph.D. in Pharmaceutical Sciences from the University of Arizona.
- Linda Pestano
琳达·佩斯塔诺于2021年10月加入Ensysce，担任首席开发官。佩斯塔诺博士在她的整个职业生涯中一直致力于指导新疗法的开发，以改善患者的治疗效果和生活质量。她拥有20年开发疫苗、药物和新型生物制剂的经验，适用于多种适应症。她在指导新疗法方面发挥了重要作用，包括小分子、核酸和生物制剂，并将其发展为临床试验。Pestano博士的专长涵盖领导开发、临床前和转化研究，以及与多个监管机构的互动。佩斯塔诺博士在塔夫茨大学获得博士学位，并在波士顿哈佛医学院的达纳法伯癌症研究所获得博士后奖学金。
Linda Pestano,joined Ensysce in October 2021, as Chief Development Officer. Dr. Pestano has worked throughout her career to guide the development of novel therapeutics to improve patient outcomes and quality of life. She has 20 years of experience developing vaccines, drugs and novel biologics for a diverse range of indications. She has been instrumental in guiding new therapies, including small molecules, nucleic acids, and biologicals through development into clinical trials. Dr. Pestano's expertise spans lead development, pre-clinical and translational studies, and interacting with multiple regulatory agencies. Dr. Pestano received her PhD from Tufts University and undertook a Post-Doctoral Fellowship with Dana Farber Cancer Institute at the Harvard Medical School in Boston.- 琳达·佩斯塔诺于2021年10月加入Ensysce，担任首席开发官。佩斯塔诺博士在她的整个职业生涯中一直致力于指导新疗法的开发，以改善患者的治疗效果和生活质量。她拥有20年开发疫苗、药物和新型生物制剂的经验，适用于多种适应症。她在指导新疗法方面发挥了重要作用，包括小分子、核酸和生物制剂，并将其发展为临床试验。Pestano博士的专长涵盖领导开发、临床前和转化研究，以及与多个监管机构的互动。佩斯塔诺博士在塔夫茨大学获得博士学位，并在波士顿哈佛医学院的达纳法伯癌症研究所获得博士后奖学金。
- Linda Pestano,joined Ensysce in October 2021, as Chief Development Officer. Dr. Pestano has worked throughout her career to guide the development of novel therapeutics to improve patient outcomes and quality of life. She has 20 years of experience developing vaccines, drugs and novel biologics for a diverse range of indications. She has been instrumental in guiding new therapies, including small molecules, nucleic acids, and biologicals through development into clinical trials. Dr. Pestano's expertise spans lead development, pre-clinical and translational studies, and interacting with multiple regulatory agencies. Dr. Pestano received her PhD from Tufts University and undertook a Post-Doctoral Fellowship with Dana Farber Cancer Institute at the Harvard Medical School in Boston.
- William Schmidt
William Schmidt，自2016年1月起担任Ensysce Biosciences, Inc.首席医疗官。他还是NorthStar Consulting的负责人、议员和美国疼痛协会最大的地区分支机构东部疼痛协会的前主席。他曾担任CrystalGenomics（韩国首尔）及其美国子公司CG Pharmaceuticals（加利福尼亚州埃默里维尔）的临床开发副总裁；Limerick BioPharma的开发高级副总裁；Renovis公司的临床研究副总裁；Adolor Corporation的科学事务副总裁和临床研究与开发代理副总裁。在Adolor Corporation，Schmidt博士是团队的关键成员，负责Entereg（alvimopan）的临床开发、NDA申请和FDA批准，Entereg（alvimopan）是一种外周作用类阿片拮抗剂。目前，施密特博士在北美、欧洲、亚洲、拉丁美洲和澳大利亚的制药和生物技术公司担任疼痛药物制药开发专家。施密特博士在加州大学伯克利分校获得文学学士学位，在加州大学旧金山分校获得博士学位。
William Schmidt,has served as Ensysce Biosciences, Inc. Chief Medical Officer since January 2016. He is also the Head of NorthStar Consulting, the Parliamentarian and a former president of the Eastern Pain Association, the largest regional affiliate of the American Pain Society. He was previously Vice President of Clinical Development for CrystalGenomics (Seoul, South Korea) and its United States subsidiary, CG Pharmaceuticals (Emeryville, CA); Senior Vice President of Development at Limerick BioPharma; Vice President, Clinical Research, for Renovis, Inc.; and Vice President, Scientific Affairs and acting Vice President, Clinical Research and Development, at Adolor Corporation. At Adolor Corporation, Dr. Schmidt was a key member of the team leading to the clinical development, NDA filing, and FDA approval of Entereg (alvimopan), a peripherally acting opioid antagonist. Currently Dr. Schmidt serves as an expert on pain medicine pharmaceutical development with pharmaceutical and biotech companies throughout North America, Europe, Asia, Latin America, and Australia. Dr. Schmidt received a Bachelor of Arts degree from the University of California Berkeley and his Ph.D. University of California-San Francisco.- William Schmidt，自2016年1月起担任Ensysce Biosciences, Inc.首席医疗官。他还是NorthStar Consulting的负责人、议员和美国疼痛协会最大的地区分支机构东部疼痛协会的前主席。他曾担任CrystalGenomics（韩国首尔）及其美国子公司CG Pharmaceuticals（加利福尼亚州埃默里维尔）的临床开发副总裁；Limerick BioPharma的开发高级副总裁；Renovis公司的临床研究副总裁；Adolor Corporation的科学事务副总裁和临床研究与开发代理副总裁。在Adolor Corporation，Schmidt博士是团队的关键成员，负责Entereg（alvimopan）的临床开发、NDA申请和FDA批准，Entereg（alvimopan）是一种外周作用类阿片拮抗剂。目前，施密特博士在北美、欧洲、亚洲、拉丁美洲和澳大利亚的制药和生物技术公司担任疼痛药物制药开发专家。施密特博士在加州大学伯克利分校获得文学学士学位，在加州大学旧金山分校获得博士学位。
- William Schmidt,has served as Ensysce Biosciences, Inc. Chief Medical Officer since January 2016. He is also the Head of NorthStar Consulting, the Parliamentarian and a former president of the Eastern Pain Association, the largest regional affiliate of the American Pain Society. He was previously Vice President of Clinical Development for CrystalGenomics (Seoul, South Korea) and its United States subsidiary, CG Pharmaceuticals (Emeryville, CA); Senior Vice President of Development at Limerick BioPharma; Vice President, Clinical Research, for Renovis, Inc.; and Vice President, Scientific Affairs and acting Vice President, Clinical Research and Development, at Adolor Corporation. At Adolor Corporation, Dr. Schmidt was a key member of the team leading to the clinical development, NDA filing, and FDA approval of Entereg (alvimopan), a peripherally acting opioid antagonist. Currently Dr. Schmidt serves as an expert on pain medicine pharmaceutical development with pharmaceutical and biotech companies throughout North America, Europe, Asia, Latin America, and Australia. Dr. Schmidt received a Bachelor of Arts degree from the University of California Berkeley and his Ph.D. University of California-San Francisco.
- D. Lynn Kirkpatrick
D. Lynn Kirkpatrick，自2009年1月起担任Ensysce Biosciences, Inc.首席执行官。柯克帕特里克博士在药物发现和开发方面花费了30多年时间，启动了四种新型候选药物的临床开发，目前正致力于将高度新颖和安全的疼痛疗法推向商业化。她在萨斯喀彻温大学获得医药和生物医药化学哲学博士（“Ph.D.”）学位，在耶鲁大学医学院完成博士后奖学金，并成为里贾纳大学化学系终身正教授。她与人共同创立了一家肿瘤发现公司ProlX Pharmaceuticals，Corp.（简称ProlX），成为首席执行官，并成功地将三个小分子的发现带入临床开发，其中两个是她自己在学术界的发现。ProlX被Biomira公司收购，柯克帕特里克博士成为合并后公司的首席科学官，专注于肿瘤产品和疫苗的开发。2009年，她与人共同创立了PHusis Therapeutics，开发针对肿瘤的小分子精准药物。同时，她成为了Ensysce Biosciences, Inc.的首席执行官。Kirkpatrick博士在靶向药物发现领域发表了大量文章，滥用具有威慑力的止痛产品，并拥有许多新药和新药的专利。
D. Lynn Kirkpatrick,has served as Ensysce Biosciences, Inc. Chief Executive Officer since January 2009. She received a Doctor of Philosophy ("Ph.D.") degree in Medicinal and Biomedicinal Chemistry at the University of Saskatchewan, completed a Post-Doctoral Fellowship at the Yale University School of Medicine, and became a tenured full professor in the Department of Chemistry at the University of Regina. She co-founded ProlX Pharmaceuticals, Corp. ("ProlX") an oncology discovery company, becoming Chief Executive Officer. ProlX was acquired by Biomira Inc., and Dr. Kirkpatrick became the Chief Scientific Officer of the merged company to focus on the development of oncology products and vaccines. In 2009, she co-founded PHusis Therapeutics, developing targeted small molecule precision medicines for oncology. At the same time, she became Ensysce Biosciences, Inc. Chief Executive Officer.- D. Lynn Kirkpatrick，自2009年1月起担任Ensysce Biosciences, Inc.首席执行官。柯克帕特里克博士在药物发现和开发方面花费了30多年时间，启动了四种新型候选药物的临床开发，目前正致力于将高度新颖和安全的疼痛疗法推向商业化。她在萨斯喀彻温大学获得医药和生物医药化学哲学博士（“Ph.D.”）学位，在耶鲁大学医学院完成博士后奖学金，并成为里贾纳大学化学系终身正教授。她与人共同创立了一家肿瘤发现公司ProlX Pharmaceuticals，Corp.（简称ProlX），成为首席执行官，并成功地将三个小分子的发现带入临床开发，其中两个是她自己在学术界的发现。ProlX被Biomira公司收购，柯克帕特里克博士成为合并后公司的首席科学官，专注于肿瘤产品和疫苗的开发。2009年，她与人共同创立了PHusis Therapeutics，开发针对肿瘤的小分子精准药物。同时，她成为了Ensysce Biosciences, Inc.的首席执行官。Kirkpatrick博士在靶向药物发现领域发表了大量文章，滥用具有威慑力的止痛产品，并拥有许多新药和新药的专利。
- D. Lynn Kirkpatrick,has served as Ensysce Biosciences, Inc. Chief Executive Officer since January 2009. She received a Doctor of Philosophy ("Ph.D.") degree in Medicinal and Biomedicinal Chemistry at the University of Saskatchewan, completed a Post-Doctoral Fellowship at the Yale University School of Medicine, and became a tenured full professor in the Department of Chemistry at the University of Regina. She co-founded ProlX Pharmaceuticals, Corp. ("ProlX") an oncology discovery company, becoming Chief Executive Officer. ProlX was acquired by Biomira Inc., and Dr. Kirkpatrick became the Chief Scientific Officer of the merged company to focus on the development of oncology products and vaccines. In 2009, she co-founded PHusis Therapeutics, developing targeted small molecule precision medicines for oncology. At the same time, she became Ensysce Biosciences, Inc. Chief Executive Officer.
- Geoff Birkett
Geoff Birkett，自2018年10月起担任Ensysce Biosciences, Inc.首席商务官。他在制药和生物技术领域拥有30多年的经验。他的职业生涯始于英国泰恩河畔纽卡斯尔皇家维多利亚医院的生物化学家。之后，他进入了制药行业，在整个职业生涯中，他专注于疼痛/成瘾和神经科学。他开发并推出了几种突破性的疗法，包括Nicorette（POM）和（OTC）、Lexapro以及其他几种灵北的精神病学药物。Birkett先生协助礼来推出Prozac和Humatrope（人类生长激素）。他协助将Seroquel从Phase 2转变为全球市场领导者，销售额达数十亿美元，他还参与了偏头痛Zomig的发布，该产品成为欧洲市场的领导者。他的大部分制药生涯都在英国和美国的阿斯利康公司工作，在那里他担任过许多职务，包括监督全球肿瘤科。当阿斯利康合并发生时，Birkett先生在美国以外的所有市场负责合并过程，并实施了一项公司改革计划，以精简涉及67,000名员工的研发工作。自离开阿斯利康以来，Birkett先生在生物技术公司担任过多个职位，担任高级官员或顾问。他是一家新型药物递送公司的联合创始人，曾为大型全球研究和咨询公司IPSOS担任顾问。他还担任过INDIVIOR北美/加拿大的总裁，这是一家生产戒毒药物的大公司。Birkett先生于2018年加入Ensysce Biosciences公司，致力于打造一支世界级的商业团队。Birkett先生曾就读于伦敦的亨利商学院和法国的欧洲工商管理学院商学院，在那里他学习了综合管理和全球领导力。
Geoff Birkett,has served as Ensysce Biosciences, Inc. Chief Commercial Officer since October 2018. He has over 30 years of experience in the Pharmaceutical and Biotechnology area. He started his career as a biochemist at the Royal Victoria Infirmary in Newcastle-upon-Tyne, England. He then moved into the pharmaceutical industry, where he focused on pain/addiction and neuroscience throughout his career. He has developed and launched several groundbreaking therapies, including Nicorette (POM) and (OTC), Lexapro and several other psychiatry agents with Lundbeck. Mr. Birkett assisted on the launch of Prozac and Humatrope (human growth hormone) with Eli Lilly. He assisted in moving Seroquel from Phase 2 to global market leader with multi-billion dollar sales and he also participated in the launch of Zomig for migraines, which became a European market leader. He worked for most of his pharmaceutical career at AstraZeneca plc in both the United Kingdom and the United States, where he held many roles including overseeing the global oncology division. When the AstraZeneca merger took place, Mr. Birkett ran the merger process outside the United States across all markets, and ran a corporate change program to streamline research and development involving 67,000 staff. Since leaving AstraZeneca, Mr. Birkett has held multiple roles in biotech companies as senior officer or as a consultant. He is co-founder of a novel drug delivery company and has consulted for IPSOS, a large global research and consulting firm. He also served as president for North America/Canada of INDIVIOR, a large company producing addiction treatment drugs. Mr. Birkett joined Ensysce Biosciences, Inc. in 2018 and is focused on building a world class commercial team. Mr. Birkett attended Henley Business College in London and INSEAD Business School in France where he studied general management and a global leadership.- Geoff Birkett，自2018年10月起担任Ensysce Biosciences, Inc.首席商务官。他在制药和生物技术领域拥有30多年的经验。他的职业生涯始于英国泰恩河畔纽卡斯尔皇家维多利亚医院的生物化学家。之后，他进入了制药行业，在整个职业生涯中，他专注于疼痛/成瘾和神经科学。他开发并推出了几种突破性的疗法，包括Nicorette（POM）和（OTC）、Lexapro以及其他几种灵北的精神病学药物。Birkett先生协助礼来推出Prozac和Humatrope（人类生长激素）。他协助将Seroquel从Phase 2转变为全球市场领导者，销售额达数十亿美元，他还参与了偏头痛Zomig的发布，该产品成为欧洲市场的领导者。他的大部分制药生涯都在英国和美国的阿斯利康公司工作，在那里他担任过许多职务，包括监督全球肿瘤科。当阿斯利康合并发生时，Birkett先生在美国以外的所有市场负责合并过程，并实施了一项公司改革计划，以精简涉及67,000名员工的研发工作。自离开阿斯利康以来，Birkett先生在生物技术公司担任过多个职位，担任高级官员或顾问。他是一家新型药物递送公司的联合创始人，曾为大型全球研究和咨询公司IPSOS担任顾问。他还担任过INDIVIOR北美/加拿大的总裁，这是一家生产戒毒药物的大公司。Birkett先生于2018年加入Ensysce Biosciences公司，致力于打造一支世界级的商业团队。Birkett先生曾就读于伦敦的亨利商学院和法国的欧洲工商管理学院商学院，在那里他学习了综合管理和全球领导力。
- Geoff Birkett,has served as Ensysce Biosciences, Inc. Chief Commercial Officer since October 2018. He has over 30 years of experience in the Pharmaceutical and Biotechnology area. He started his career as a biochemist at the Royal Victoria Infirmary in Newcastle-upon-Tyne, England. He then moved into the pharmaceutical industry, where he focused on pain/addiction and neuroscience throughout his career. He has developed and launched several groundbreaking therapies, including Nicorette (POM) and (OTC), Lexapro and several other psychiatry agents with Lundbeck. Mr. Birkett assisted on the launch of Prozac and Humatrope (human growth hormone) with Eli Lilly. He assisted in moving Seroquel from Phase 2 to global market leader with multi-billion dollar sales and he also participated in the launch of Zomig for migraines, which became a European market leader. He worked for most of his pharmaceutical career at AstraZeneca plc in both the United Kingdom and the United States, where he held many roles including overseeing the global oncology division. When the AstraZeneca merger took place, Mr. Birkett ran the merger process outside the United States across all markets, and ran a corporate change program to streamline research and development involving 67,000 staff. Since leaving AstraZeneca, Mr. Birkett has held multiple roles in biotech companies as senior officer or as a consultant. He is co-founder of a novel drug delivery company and has consulted for IPSOS, a large global research and consulting firm. He also served as president for North America/Canada of INDIVIOR, a large company producing addiction treatment drugs. Mr. Birkett joined Ensysce Biosciences, Inc. in 2018 and is focused on building a world class commercial team. Mr. Birkett attended Henley Business College in London and INSEAD Business School in France where he studied general management and a global leadership.